Facing the relapse of acute lymphoblastic leukemia (ALL) can feel overwhelming, but at GoBroad, we understand the unique challenges of this journey and are committed to delivering personalized, evidence-based care that offers hope even in the most complex cases. As someone who has witnessed the resilience of patients and the dedication of our team, I’m honored to share how GoBroad—through its specialized institutions like the Nanfang-Chunfu Children's Institute of Hematology—combines advanced diagnostics, innovative therapies, and compassionate support to address relapse with precision and care.

About GoBroad’s Specialized Pediatric Hematology Care

At GoBroad Healthcare Group, our mission to “Questing for Excellence in Diagnosis&Treatment, Exploring Technological Innovation, Create Possibilities in Life” is deeply reflected in our approach to pediatric hematologic cancers. The Nanfang-Chunfu Children's Institute of Hematology, led by Professor Chunfu Li and partnered with the Mayo Clinic, stands as a global leader in pediatric oncology and hematology. Located within Dongguan Taixin Hospital, our facility boasts 150 standard beds and 36 specialized transplant suites, equipped to handle even the most challenging cases of ALL relapse. We focus on integrating medical treatment, research, and education, ensuring that children with relapsed ALL receive care that combines clinical expertise with the latest advancements in hematopoietic stem cell transplantation (HSCT) and cellular therapies.

Precision Diagnosis: Uncovering the Roots of Relapse

The first step in addressing relapse of acute lymphoblastic leukemia is understanding why it occurred. At GoBroad, we use a comprehensive diagnostic system that combines genetic sequencing, flow cytometry, and molecular profiling to identify residual disease and genetic mutations that may drive relapse. For example, we assess markers like BCR-ABL1 or CD19 expression to determine if cancer cells have developed resistance to prior treatments. Our team also evaluates the bone marrow and cerebrospinal fluid to check for minimal residual disease (MRD), a critical factor in tailoring rescue strategies. This detailed approach ensures we uncover the unique biological drivers of relapse, allowing us to design therapies that target remaining cancer cells with precision.

Innovative Therapies: Tailored Solutions for Relapsed ALL

Relapsed ALL often requires advanced interventions, and our institute specializes in leveraging cutting-edge therapies to overcome treatment resistance. One cornerstone of our approach is hematopoietic stem cell transplantation (HSCT), including haploidentical transplants, which we’ve performed in 69.77% of cases from 2018 to 2024. Our novel protocol for T-cell depletion in allogeneic HSCT (TDH) has been pivotal in reducing graft-vs-host disease (GvHD) and improving outcomes for relapsed ALL, especially when combined with targeted agents or CAR-T cell therapy. For instance, we’ve used CD19 CAR-T therapy to eliminate residual leukemia cells in patients with relapsed B-cell ALL, achieving deep remission before proceeding with transplant. These therapies are supported by our state-of-the-art facilities, ensuring patients receive high-quality care from diagnosis through recovery.

Multidisciplinary Support: Nurturing Body, Mind, and Hope

Caring for relapsed ALL requires more than medical expertise; it demands a holistic approach that addresses the physical and emotional needs of patients and families. Our multidisciplinary team—including hematologists, oncologists, psychologists, and pediatric specialists—works together to create personalized care plans that balance aggressive treatment with supportive services. We offer nutritional counseling to manage treatment-related side effects, psychological support to navigate the emotional toll of relapse, and educational resources to empower families with knowledge about each step of the journey. Additionally, our international collaborations, such as with the Mayo Clinic, ensure we stay at the forefront of global advancements, bringing proven strategies and innovative clinical trials to our patients.

Conclusion

Relapse of acute lymphoblastic leukemia is a daunting challenge, but at GoBroad, we meet it with expertise, innovation, and unwavering support. Our specialized pediatric hematology institute, led by world-class experts and equipped with advanced therapies like HSCT and CAR-T cell treatment, is dedicated to rewriting the story for children and families facing relapse. We understand that every patient is unique, and our commitment to precision diagnosis, innovative treatment, and compassionate care ensures that no detail is overlooked. Trust in our legacy of excellence—because at GoBroad, we don’t just treat relapse; we strive to create possibilities for healing, one personalized plan at a time.